In this presentation from the Clinical Track at the 2017 Advances in Inflammatory Bowel Diseases conference, Dr. Gary R. Lichtenstein discusses the treatment of moderate to sever IBD with anti-TNF biologics and immunomodulators.

Earn CME credit for this activity at the following location:
[ Ссылка ]

© 2017 Imedex, LLC.

свернуть